Business
Positive Evaluation of Parsortix System
Positive Evaluation of Parsortix System.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 0845K Angle PLC 25 July 2013 \n \n\n\n\n\n\nFor immediate release \n \n\n\n25 July 2013\n\n\n\n\n \nANGLE plc \n(\"ANGLE\" or \"the Company\")\n \nPOSITIVE EVALUATION OF PARSORTIX SYSTEM FROM \nCANCER RESEARCH UK'S PATERSON INSTITUTE FOR CANCER RESEARCH \n \n \nANGLE plc (AIM: AGL), the specialist medtech company, is pleased to announce further encouraging results from third party testing of its Parsortix non-invasive cancer diagnostic product. \n \nThe Parsortix system is aimed at the isolation and characterisation of circulating tumour cells (CTCs) present in cancer patient blood samples based on the physical properties of CTCs rather than the presence of specific cell markers on CTCs.\n \nThe Parsortix system, comprising the PR1 machine and the GEN3 cassette, has been evaluated at Cancer Research UK's Paterson Institute for Cancer Research (the Paterson) within The University of Manchester. Cancer cell lines were utilised that were known to give particularly good results with the existing FDA approved system as a result of their strong cell markers. In control experiments, where these cell lines were \"spiked\" into healthy blood, the Parsortix device performed well and gave comparable enumeration to the existing FDA approved system using cell markers for CTC isolation. \n \nOngoing clinical studies are now underway at the Paterson with blood samples from patients with lung cancer and melanoma to test whether the Parsortix system can contribute to the molecular characterisation of CTCs captured via a method independent of cell markers. The Parsortix system, which incorporates physical separation of CTCs, is being used because both lung and melanoma CTCs are heterogeneous compromising any approach using a single cell surface marker for their capture. \n \nIn addition to the clinical studies, a pilot study at the Paterson is also evaluating the suitability of the Parsortix system for the analysis of small volumes of blood from mice harbouring human CTC derived tumours. Preliminary results look promising with CTCs detected using the Parsortix system in mouse blood samples. Ongoing work is now focused on molecular analysis of CTCs harvested by the Parsortix system. \n \nThe major advantages of the ...